spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  acute chest syndrome 

 HSMN NewsFeed - 24 Sep 2019
Emmaus Life Sciences Reinforces Positive Outcomes of Endari(R) Clinical Trials, Including Efficacy Findings That Led to FDA Approval
Biopharmaceuticals
 HSMN NewsFeed - 12 Mar 2012
HemaQuest Pharmaceuticals Raises $13 Million in Series B Extension Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 14 Feb 2011
ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Feb 2010
Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 18 Dec 2007
Anthera's A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Dec 2007
Anthera Pharmaceuticals Names Christopher P. Lowe Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Apr 2007
First Patient Enrolled in Phase 2 'PLASMA' Trial With A-002 for Patients With Coronary Atherosclerosis
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 20 Mar 2007
Anthera Pharmaceuticals, Inc. Announces Appointment of Dr. James Pennington as Executive Vice President & Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Mar 2007
Anthera Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board for Respiratory and Acute Care Programs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Feb 2007
Dr. David D. Waters Joins Anthera Pharmaceuticals as Cardiovascular Research Fellow
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jan 2007
Anthera Receives IND Approval from FDA to Begin Phase 2 'IMPACTS' Trial With A-001 for Prevention of Acute Chest Syndrome in Patients with Sickle Cell Disease
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2007
Anthera Receives FDA Approval to Begin Phase 2 'PLASMA' Trial With A-002 for Patients With Coronary Atherosclerosis
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 13 Sep 2006
Anthera Pharmaceuticals Secures $36M Venture Financing to Initiate Clinical Programs
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Sep 2006
Anthera Licenses Portfolio of Anti-Inflammatory Products From Eli Lilly and Company and Shionogi & Co., Ltd.
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 1 additional stories matching:
acute chest syndrome
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!